We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
Read MoreHide Full Article
Bruker Corporation (BRKR - Free Report) , a renowned name in the field of proprietary life science and materials research systems, recently announced the buyout of InVivo Biotech Services GmbH. This Hennigsdorf, Germany-based company is a molecular biology contract manufacturing organization (CMO) and a leading provider of monoclonal antibodies and recombinant proteins. InVivo Biotech also has significant experience in the development and production of innovative immunoassay components and research kits. Financial details of the transaction have been kept under wraps.
Over the last six months, Bruker has been going through a rough phase as its share price underperformed the Instruments - Scientific industry trend. In fact, weak organic revenues in recent times have been a matter of concern. Currently, the stock is down 4.6% compared to 3.1% decline of the broader industry.
On a bright side, management saw an improvement in margins in the last reported quarter on the back of several businesses among which Bruker CALID franchise is one. The Bruker CALID comprises the Bruker Daltonics division which primarily manufactures and distributes life science mass spectrometry instruments. We expect the acquisition of InVivo Biotech to boost the Bruker Daltonics division further.
The acquired company offers a complete range of biotech services, from cloning, screening and recombinant expression of antigens to the generation of hybridoma cell lines, and from characterization of antibodies to final production of the developed monoclonal antibodies. InVivo Biotech's selection of bacterial, insect and mammalian protein expression systems provides a wide range of choices for various applications, taking into account specific customer needs.
Management claims that the acquisition will support its strategy of expanding its microbiology assay menu for its MALDI Biotyper platform. The platform which falls under the Bruker Daltonics division has been developed for the analysis of microorganisms. The platform is believed to have higher potential to contribute significantly to the company’s top line over time. InVivo Biotech’s expertise in monoclonal antibodies opens new possibilities to combine the specificity of antibody enrichment with the multi-channel information read-out through the MALDI Biotyper platform.
As per a MarketsandMarkets report, the global mass spectrometry market is expected to reach a worth of $7,279.1 million by 2020, at a CAGR of 8.1%. Due to the rise in the aging population and the growing incidence of diseases, especially caused by microorganisms, Bruker is currently working on gaining traction in this growing market.
Impressively, Bruker’s MALDI Biotyper franchise has grown into approximately $90 million systems per annum. In 2016, the company introduced Rapiflex MALDI-TOFTOF for detailed protein characterization in life science research and biopharmaceutical laboratories. The company also launched MBT Biotargets, which helps reduce operator error and save time in running tests on the Biotyper solution. Bruker further introduced research use-only capabilities to the MALDI Biotyper product portfolio for rapid testing of strains and selected antibiotic resistant mechanisms. Based on the recent developments witnessed in this product portfolio, management believes Bruker is poised to double its microbiology business over the next four to five years.
ICU Medical gained 36.9% over the last one year compared with the S&P 500’s 14.1%. The company has a four-quarter average positive earnings surprise of 46.3%.
Align Technology rallied 50.7% in the past one year, way better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 23%.
Haemonetics recorded a 27.8% gain over the past one year, better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 0.82%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Bruker Buys InVivo Biotech, Boosts MALDI Biotyper Suite
Bruker Corporation (BRKR - Free Report) , a renowned name in the field of proprietary life science and materials research systems, recently announced the buyout of InVivo Biotech Services GmbH. This Hennigsdorf, Germany-based company is a molecular biology contract manufacturing organization (CMO) and a leading provider of monoclonal antibodies and recombinant proteins. InVivo Biotech also has significant experience in the development and production of innovative immunoassay components and research kits. Financial details of the transaction have been kept under wraps.
Over the last six months, Bruker has been going through a rough phase as its share price underperformed the Instruments - Scientific industry trend. In fact, weak organic revenues in recent times have been a matter of concern. Currently, the stock is down 4.6% compared to 3.1% decline of the broader industry.
On a bright side, management saw an improvement in margins in the last reported quarter on the back of several businesses among which Bruker CALID franchise is one. The Bruker CALID comprises the Bruker Daltonics division which primarily manufactures and distributes life science mass spectrometry instruments. We expect the acquisition of InVivo Biotech to boost the Bruker Daltonics division further.
The acquired company offers a complete range of biotech services, from cloning, screening and recombinant expression of antigens to the generation of hybridoma cell lines, and from characterization of antibodies to final production of the developed monoclonal antibodies. InVivo Biotech's selection of bacterial, insect and mammalian protein expression systems provides a wide range of choices for various applications, taking into account specific customer needs.
BRUKER CORP Price
BRUKER CORP Price | BRUKER CORP Quote
Management claims that the acquisition will support its strategy of expanding its microbiology assay menu for its MALDI Biotyper platform. The platform which falls under the Bruker Daltonics division has been developed for the analysis of microorganisms. The platform is believed to have higher potential to contribute significantly to the company’s top line over time. InVivo Biotech’s expertise in monoclonal antibodies opens new possibilities to combine the specificity of antibody enrichment with the multi-channel information read-out through the MALDI Biotyper platform.
As per a MarketsandMarkets report, the global mass spectrometry market is expected to reach a worth of $7,279.1 million by 2020, at a CAGR of 8.1%. Due to the rise in the aging population and the growing incidence of diseases, especially caused by microorganisms, Bruker is currently working on gaining traction in this growing market.
Impressively, Bruker’s MALDI Biotyper franchise has grown into approximately $90 million systems per annum. In 2016, the company introduced Rapiflex MALDI-TOFTOF for detailed protein characterization in life science research and biopharmaceutical laboratories. The company also launched MBT Biotargets, which helps reduce operator error and save time in running tests on the Biotyper solution. Bruker further introduced research use-only capabilities to the MALDI Biotyper product portfolio for rapid testing of strains and selected antibiotic resistant mechanisms. Based on the recent developments witnessed in this product portfolio, management believes Bruker is poised to double its microbiology business over the next four to five years.
Zacks Rank & Key Picks
Bruker carries a Zacks Rank #3 (Hold). Better-ranked medical stocks are ICU Medical Inc. (ICUI - Free Report) , Align Technology, Inc. (ALGN - Free Report) and Haemonetics Corporation (HAE - Free Report) . ICU Medical and Align Technology sport a Zacks Rank #1 (Strong Buy) while Haemonetics carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
ICU Medical gained 36.9% over the last one year compared with the S&P 500’s 14.1%. The company has a four-quarter average positive earnings surprise of 46.3%.
Align Technology rallied 50.7% in the past one year, way better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 23%.
Haemonetics recorded a 27.8% gain over the past one year, better than the S&P 500. It has a trailing four-quarter average positive earnings surprise of 0.82%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>